DAWN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Day One Biopharmaceuticals Inc (DAWN) is not a good buy for a long-term beginner investor at this time. The stock is being acquired by Servier for $21.50 per share in cash, which caps its upside potential. Analysts have downgraded the stock to Neutral, and there are no significant positive catalysts or trading signals to suggest further growth opportunities.
The technical indicators show a neutral to slightly bearish trend. The MACD is below 0 and negatively contracting, while the RSI is neutral at 64.688. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its acquisition price of $21.50, limiting further upside.
NULL. The acquisition by Servier at $21.50 per share in cash sets a ceiling on the stock's price.
The acquisition agreement limits upside potential. Analysts have downgraded the stock to Neutral, and there are no recent news or significant trading trends to suggest further growth.
In Q4 2025, revenue increased by 83.92% YoY to $53.72 million, but net income dropped by 67.62% YoY to -$21.28 million. EPS also declined by 67.19% YoY to -$0.21, and gross margin slightly dropped to 88.68%. While revenue growth is strong, profitability remains a concern.
Analysts have downgraded the stock to Neutral following the acquisition announcement. The price target has been set at $21.50, aligning with the acquisition price. Previous ratings and targets were higher, but the acquisition has capped expectations.
